Ocular event management. (A-B) Ocular ARs and OEFs were used to assess ocular events (A) and OEFs drove protocol-recommended belamaf dose modification (B). ∗Examination findings were reported as AEs before implementation of KVA scale. ^†Dose modification should be based on the most severe finding. If eyes differ in severity, the dose modification guideline should be applied based on the more severe eye. ^‡Corneal ulcer is defined as an epithelial defect with underlying stromal infiltration. ^§Changes in visual acuity due to treatment-related corneal findings. CTCAE, Common Terminology Criteria for Adverse Events; NA, not applicable; Q3W, every 3 weeks.